Anti-Obesity Medications: Inside and Outside the Label

70% of US adults have obesity or pre-obesity and only 2% are offered pharmacology treatment as part of the evidenced based treatment. It is important for clinicians to know the full evidenced-based management of the disease of obesity. During this presentation the participant will review FDA approved medications and discuss off label options to assist with treatment.

*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.

Credits: 1.0 Contact Hours; 1.0 are Pharmacology
This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid from 2/11/2025 to 2/10/2026. PAs should only claim credit commensurate with the extent of their participation
Expiration Date: February 10, 2026

$35

LEARNING OBJECTIVES

After taking part in this educational activity, participants should be better able to:

-Recognize the role of pharmacotherapy in obesity treatment.
-Evaluate FDA approved medications for the pharmacologic management of chronic disease of obesity.
-Identify available pharmacotherapeutics that can be utilized to support treatment of chronic disease of obesity that are not labeled for obesity by the FDA 20 minutes

CE/CME INFORMATION

Obtain Your Credits

To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned'  for future access.

Designation Statement

NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 1.0 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.

This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid from 2/11/2025 to 2/10/2026 . 

Accreditation Statement

Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

In addition to ANCC, NPACE is approved as a provider of continuing education in nursing by: the California Board of Registered Nursing, Provider Number CEP8720

This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid from 2/11/2025 to 2/10/2026. PAs should only claim credit commensurate with the extent of their participation.

DISCLOSURES

Faculty

Contributing faculty, Angie Golden, DNP, FNP-C, FAANP, FOMA  has disclosed:

Novo Nordisk Promotional speaker, Advisor Obesity Wegovy
Eli Lilly Promotional speaker, Advisor Obesity Zepbound
Currax Promotional speaker, Advisor Obesity Contrave
BI Consultant, Advisor Obesity No specific medication yet
WW Advisor Obesity NA
Acella Promotional speaker, Advisor Thyroid NPThyroid

Planners

All planners and contributors involved in this educational activity have disclosed no relevant financial relationships. 

Disclaimer

The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.

Disclosure of Unlabeled Use

This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

There is no commercial support for this activity.